IgGenix is a pre-clinical antibody discovery and development company based in South San Francisco focused on treating severe allergies. Using its proprietary SEQ SIFTER single-cell genomics platform, the company isolates rare IgE-producing B cells to identify and re-engineer fully human, high-affinity, allergen-specific IgG antibodies. Its lead program targets peanut allergy and involves re-engineered IgE monoclonal antibodies designed to block and prevent allergic reactions. The company plans to advance the lead program into Phase 1 human clinical trials and to expand its discovery platform to additional IgE-mediated diseases beyond allergy. IgGenix announced a $40M Series B first close to fund these efforts. Co-founders include Stephen Quake, Kari Nadeau and Derek Croote, and Joel S. Marcus recently joined the board following the financing. IgGenix applies cutting-edge single-cell genomics to isolate rare IgE-producing B cells and reengineer those allergen-specific antibodies into IgG therapeutics. Its SeqSifter high-throughput discovery platform has uncovered thousands of monoclonal, allergen-specific, high-affinity antibodies from highly allergic individuals. The company was founded based on research by Stanford professors Stephen Quake, Kari Nadeau and Derek Croote and aims to deliver first-in-class therapies with faster onset and more sustained clinical responses. IgGenix will use proceeds from an oversubscribed $25 million Series A1 to expand its discovery platform across food and nonfood allergies and to accelerate its lead program into preclinical development. The company positions its approach as having the potential to prevent life-threatening allergic reactions and improve quality of life for people with severe allergies. IgGenix is based in South San Francisco, California. IgGenix is a privately held biotechnology company developing antibody-based therapeutics to treat food and non-food allergies and other severe allergic conditions. Its platform captures and analyzes very rare human B cells that express allergen-binding antibodies and engineers them with immune-modulating activities derived from the IgG antibody class to suppress allergic reactions. The company isolates and transforms allergen-specific IgE antibodies into IgG antibodies designed to alleviate and possibly prevent the allergic cascade. Co-founder Derek Croote is the lead author of a Science paper that first characterized single human IgE B cells, and the company leverages single-cell genomic and related technologies in its discovery approach. IgGenix announced the appointment of Richard Boismenu, Ph.D., as chief scientific officer and named co-founder Derek Croote as chief technical officer. The company says it will use new financing to advance its antibody therapeutics platform and develop first-in-class therapies for millions of allergy sufferers.

Total raised

$75M

Funding rounds

3

Latest round

Series B

Latest activity

Feb 2023